RNAseq. Genomic and Transcriptomic Quality Control for an Autologous iPSC-Derived Cell Therapy for Parkinson’s Disease

This DAC oversees access to genomic and transcriptomic datasets derived from dopaminergic neuron replacement research studies, including data from preclinical and clinical investigations into Parkinson’s disease and related neurodegenerative conditions. Terms and Conditions: Data may be accessed by registered academic researchers with approved institutional ethics protocols. Data use is restricted to non-commercial biomedical research. Re-identification of individuals is strictly prohibited and constitutes a breach of the Data Access Agreement. Data must be stored on secure, access-controlled systems compliant with institutional and national data protection regulations. Publications using the data must cite the dataset accession number and acknowledge the DAC. A publication embargo of 12 months from the dataset release date applies. Access is restricted to institutions located in jurisdictions with reciprocal data protection agreements. The DAC reserves the right to deny access based on institutional location or legal incompatibility. Access may also be contingent upon establishing a formal collaboration agreement with the data provider, at the discretion of the DAC. DUO Codes: DUO:0000007 – Disease-specific research Modifier: MONDO:0005180 (Parkinson's disease) DUO:0000015 – No general methods research DUO:0000018 – Non-commercial use only DUO:0000021 – Research use only (ethics approval required) DUO:0000022 – Geographical restriction